Halozyme Therapeutics beats by $0.03, beats on revenue Halozyme Therapeutics (NASDAQ:HALO): Q4 EPS of -$0.04 beats by $0.03. Revenue of $30.4M (+143.2% Y/Y) beats by $4.81M. Shares +4.8%.